Myriad Genetics (NASDAQ:MYGN) Issues FY 2025 Earnings Guidance

Myriad Genetics (NASDAQ:MYGN) updated its FY 2025 earnings guidance on Wednesday. The company provided EPS guidance of 0.070-0.110 for the period, compared to the consensus EPS estimate of 0.090. The company issued revenue guidance of $840.0 million-$860.0 million, compared to the consensus revenue estimate of $883.1 million. Myriad Genetics also updated its FY25 guidance to $0.07-0.11 EPS.

Analysts Set New Price Targets

A number of equities analysts have recently commented on MYGN shares. Leerink Partners cut Myriad Genetics from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $30.00 to $21.00 in a research report on Monday, December 9th. Piper Sandler lowered their target price on shares of Myriad Genetics from $30.00 to $24.00 and set a “neutral” rating on the stock in a research note on Monday, November 11th. Leerink Partnrs lowered shares of Myriad Genetics from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 9th. Bank of America dropped their price objective on Myriad Genetics from $15.00 to $13.00 and set an “underperform” rating for the company in a research note on Friday, December 13th. Finally, Stephens restated an “equal weight” rating and issued a $20.00 target price on shares of Myriad Genetics in a research note on Thursday. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $23.92.

Myriad Genetics Stock Down 4.8 %

Shares of Myriad Genetics stock opened at $12.52 on Friday. The company has a quick ratio of 1.73, a current ratio of 1.90 and a debt-to-equity ratio of 0.05. Myriad Genetics has a one year low of $12.17 and a one year high of $29.30. The business’s 50 day simple moving average is $14.78 and its two-hundred day simple moving average is $21.97.

About Myriad Genetics

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.